Abstract
Morbid obesity remains a strong risk factor limiting cardiac and liver transplantation. Furthermore, studies have demonstrated that morbidly obese transplant recipients have nearly twice the 5-year mortality of normal-weight or overweight recipients, thereby preventing morbidly obese patients from undergoing a heart or liver transplant. We compare the use of AGB as a mode of weight loss for patients considering heart and liver transplant surgery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
